Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Aug 08 2022

• By Jessica Merrill

Listen to this article

Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.

Sickle Cell Disease — Pfizer is expanding in the sickle cell disease space with GBT acquisition • Source: Shutterstock

Pfizer Inc. is continuing to execute on a business development strategy centered on bringing in marketed drugs or late-stage pipeline opportunities with its latest acquisition – the sickle cell disease specialist Global Blood Therapeutics, Inc. for $5.4bn. The two companies announced they had reached an agreement for Pfizer to acquire the company for $68.50 per share in cash on 8 August.

Pfizer said the acquisition of GBT will expand its heritage in the area of rare hematology, though it marks its...

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone
Feb 04 2026
• By Urtė Fultinavičiūtė
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US
Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod
Aug 15 2024
• By Alaric DeArment
US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.
Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III
Jul 24 2024
• By Jessica Merrill
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.
Abecma Or Bust: 2seventy Sells Final Research Program To Novo
Jun 27 2024
• By Jessica Merrill
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.